We are live on ! Find out more
MBRX icon

Moleculin Biotech
MBRX

10 hedge funds and large institutions have $1.58M invested in Moleculin Biotech in 2018 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

1,267% more capital inflows, than outflows

Capital inflows: $287K | Capital outflows: $21K

25% more funds holding

Funds holding: 8 → 10 (+2)

0.8% more ownership

Funds ownership: 4.78% → 5.58% (+0.8%)

Holders
10
Holders Change
+2
Holders Change %
+25%
% of All Funds
0.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CIBC World Market
CIBC World Market
Ontario, Canada
+$115K
2
Bank of New York Mellon
Bank of New York Mellon
New York
+$57.4K
3
Renaissance Technologies
Renaissance Technologies
New York
+$57.4K
4
Whitegate Investment Counselors
Whitegate Investment Counselors
New Hampshire
+$57.4K

Top Sellers

Rank Fund Capital Flow
1
PNC Financial Services Group
PNC Financial Services Group
Pennsylvania
-$13K
2
Avondale Wealth Management
Avondale Wealth Management
Texas
-$4K
3
OneDigital Investment Advisors
OneDigital Investment Advisors
Kansas
-$4K

MBRX Hedge Fund Activity: Q4 2018 in Review

10 of the 4,506 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q4 2018, worth a combined $1.58M — down 23% from $2.05M a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new MBRX positions and 0 closed out — a net gain of 2 holders — while 2 added to existing stakes and 0 trimmed.

The largest buyer was CIBC World Market, adding an estimated $115K. The largest seller was PNC Financial Services Group, cutting an estimated $13K.

  • 10 institutional investors held Moleculin Biotech (MBRX) as of Q4 2018, up from 8 in Q3 2018.
  • Funds reported $1.58M of Moleculin Biotech stock for Q4 2018, down 23% quarter-over-quarter.
  • 2 funds opened new Moleculin Biotech positions in Q4 2018 and 0 closed out, a net change of +2 holders.
  • The largest Moleculin Biotech buyer in Q4 2018 was CIBC World Market, an estimated $115K added.
  • The largest Moleculin Biotech seller in Q4 2018 was PNC Financial Services Group, an estimated $13K sold.

Based on aggregated 13F filings for Q4 2018.